Neurocrine Biosciences
NBIX
NBIX
325 hedge funds and large institutions have $7.8B invested in Neurocrine Biosciences in 2019 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 142 increasing their positions, 98 reducing their positions, and 49 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
8% less first-time investments, than exits
New positions opened: 45 | Existing positions closed: 49
2% less funds holding
Funds holding: 330 → 325 (-5)
2.79% less ownership
Funds ownership: 100.24% → 97.45% (-2.8%)
Holders
325
Holding in Top 10
7
Calls
$108M
Puts
$77.1M
Top Buyers
| 1 | +$118M | |
| 2 | +$79.4M | |
| 3 | +$65.9M | |
| 4 |
DCP
DSM Capital Partners
Palm Beach Gardens,
Florida
|
+$61.3M |
| 5 |
Millennium Management
New York
|
+$47.5M |
Top Sellers
| 1 | -$227M | |
| 2 | -$122M | |
| 3 | -$93.1M | |
| 4 |
PA
Perceptive Advisors
New York
|
-$74.9M |
| 5 |
TCM
TimesSquare Capital Management
New York
|
-$62M |